NineSights Community - Request for Proposal: 2aNew Drug Modality Targeting Immunosuppr... - 0 views
-
MiamiOH OARS on 12 Mar 19NineSigma, representing Sumitomo Dainippon Pharma Co., Ltd. (https://www.ds-pharma.com/) ("Client"), seeks a drug modality for novel anti-cancer drugs that target immunosuppressive cells and interfere with immune functions, or an evaluation system for creating a drug modality. In recent years, the emergence of immune checkpoint inhibitors has been gradually revealing that the local immunosuppressive environment in tumor affects cancer treatment. This attracts interest in the development of novel antitumor drugs for improving the immune state of the tumor microenvironment. In particular, we look for compounds that target host cells contributing to the formation of the immunosuppressive environment and interfering with these functions. Focusing on cancer as its key area and considering the development of novel unique products to be its basic strategy, the Client decided to seek a partner with whom it can provide novel drugs to the market as soon as possible based on the above concept.